Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMO | O15229 | 18/20 | 0.46 |
| ▸ | GRN | P28799 | 2/20 | 0.42 |
| ▸ | SORT1 | Q99523 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31229420 | 0.86 | KMO (0.44) | KMOKDM4E | |
| SCHEMBL24714018 | 0.82 | CDK8 (0.43) | GRNSORT1KDM4E | |
| SCHEMBL7870780 | 0.80 | KMO (0.51) | KMOKDM4E | |
| SCHEMBL24714758 | 0.79 | LMNA (0.35) | GRNSORT1KDM4E | |
| SCHEMBL22644506 | 0.79 | MAPK1 (0.40) | KDM4E | |
| SCHEMBL24714761 | 0.79 | BAZ2B (0.39) | KDM4E | |
| SCHEMBL71141 | 0.78 | KMO (0.59) | KMOKDM4E | |
| Hydrochloric Acid SCHEMBL3272233 | 0.75 | KMO (0.57) | KMOKDM4E | |
| Fluoride SCHEMBL21173953 | 0.75 | KMO (0.57) | KMOKDM4E | |
| Hydrochloric Acid SCHEMBL3272369 | 0.75 | KMO (0.57) | KMOKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11746095-B2 | Inhibtors of RAF kinases | KINNATE BIOPHARMA INC. (US) | 2023-09-05 | — | — | US | disclosed |
| US-11746095-B2 | Inhibtors of RAF kinases | KINNATE BIOPHARMA INC. (US) | 2023-09-05 | — | — | US | disclosed |
| US-11746095-B2 | Inhibtors of RAF kinases | KINNATE BIOPHARMA INC. (US) | 2023-09-05 | — | — | US | disclosed |
| US-20220356160-A1 | INHIBITORS OF RAF KINASES | Pierre Fabre Médicament (FR) | 2022-11-10 | — | — | US | disclosed |
| US-11377431-B2 | Inhibitors of RAF kinases | KINNATE BIOPHARMA INC. (US) | 2022-07-05 | — | — | US | disclosed |
| US-11377431-B2 | Inhibitors of RAF kinases | KINNATE BIOPHARMA INC. (US) | 2022-07-05 | — | — | US | disclosed |
| WO-2022081469-A1 | INHIBITORS OF RAF KINASES | KINNATE BIOPHARMA INC. (US) | 2022-04-21 | — | — | WO | disclosed |
| WO-2022081469-A1 | INHIBITORS OF RAF KINASES | KINNATE BIOPHARMA INC. (US) | 2022-04-21 | — | — | WO | disclosed |
| US-20220112170-A1 | INHIBITORS OF RAF KINASES | Pierre Fabre Médicament (FR) | 2022-04-14 | — | — | US | disclosed |
| US-20220112170-A1 | INHIBITORS OF RAF KINASES | Pierre Fabre Médicament (FR) | 2022-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220112170-A1 | INHIBITORS OF RAF KINASES | BRAF, RAF1, ARAF | KMO 3457/4885GRN 3758/4885SORT1 2708/4885 |
| US-11746095-B2 | Inhibtors of RAF kinases | RAF1, BRAF, ARAF | KMO 3975/4885GRN 3189/4885SORT1 3536/4885 |
| US-20220356160-A1 | INHIBITORS OF RAF KINASES | BRAF, RAF1, ARAF | KMO 3457/4885GRN 3758/4885SORT1 2708/4885 |
| US-11377431-B2 | Inhibitors of RAF kinases | BRAF, RAF1, ARAF | KMO 3457/4885GRN 3758/4885SORT1 2708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.